STAAR Surgical's stock (STAA) took a sharp 5.02% dive during Wednesday's intraday trading session, as tensions escalated over a proposed takeover by Swiss eyecare giant Alcon. The sudden drop comes on the heels of a dramatic move by the company's largest shareholder, Broadwood Partners, to remove several board members.

Broadwood Partners, which owns a substantial 27.5% stake in STAAR Surgical, announced its intention to call a special shareholder meeting with the aim of ousting multiple directors from the board. This aggressive stance is directly tied to what Broadwood describes as "overwhelming shareholder opposition" to Alcon's proposed acquisition of STAAR. The investment firm argues that the current board "no longer has the confidence of shareholders" and that new directors are needed to "properly steward the Company and restore shareholder trust."

The timing of this announcement is particularly significant, as STAAR Surgical shareholders are scheduled to vote on the proposed $1.5 billion acquisition deal on Thursday. Alcon's offer of $28 per share, approved by both companies' boards in early August, has faced mounting criticism. In addition to Broadwood's opposition, at least two other investors, Yunqi Capital and Defender Capital, have also voiced their objections, bringing the total opposition to nearly 34% of outstanding shares. Furthermore, proxy advisory firm Institutional Shareholder Services has recommended that investors reject the offer, citing "various deficiencies, disconnects, and uncertainties" associated with the deal. As the market digests these developments, STAAR Surgical's stock price reflects the growing uncertainty surrounding the company's future direction and leadership.